Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
23.30
-0.64 (-2.67%)
Sep 11, 2026, 4:00 PM EDT - Market closed

Aktis Oncology Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
1,296----
Market Cap Growth
-----
Enterprise Value
790----

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Debt / Equity Ratio
0.020.060.050.130.01
Debt / FCF Ratio
--1.01--
Net Debt / Equity Ratio
-1.04-1.15-1.16-0.81-0.97
Net Debt / EBITDA Ratio
6.002.985.652.516.57
Net Debt / FCF Ratio
5.982.92-23.962.506.21
Asset Turnover
-0.020.01--
Quick Ratio
16.177.3015.8515.7424.38
Current Ratio
16.337.3715.9816.0725.12
Return on Equity (ROE)
--29.45%-25.18%-24.42%-
Return on Assets (ROA)
--15.79%-14.51%-16.68%-
Return on Capital Employed (ROCE)
-16.60%-32.00%-16.90%-30.00%-14.90%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Buyback Yield / Dilution
-3649.41%-15.53%-14.46%-18.90%-
SEC Filings: 10-K · 10-Q